[ET Net News Agency, 13 December 2021] INNOVENT BIO (01801) fell 5.2% to HK$62.85.
It hits an intra-day low of HK$62.85, and an intra-day high of HK$66.7. The total shares
traded was 3.49 million, with a value of HK$223.14m. The active buy/sell ratio is 53:47,
with net buying turnover of HK$12.72m. CHINA INNOVATION MARKET SER accounts for greatest
net responsive buying turnover of HK$14.99m, with volume weighted average price of
HK$63.857. CREDIT SUISSE (HK) SEC accounts for greatest net responsive selling turnover of
HK$16.11m, with volume weighted average price of HK$64.107. The stock has fallen a
combined 7.37% over the past 2 consecutive trading days.
The Hang Seng Index now rose 241 points, or 1.01% to 24,237; the Hang Seng China
Enterprises Index now rose 80 points, or 0.94% to 8,658; the Hang Seng TECH Index now rose
80 points, or 1.33% to 6,115; with an overall turnover of HK$72.34b.
The SSE Composite Index now rose 36 points, or 1% to 3,702, with an overall turnover of
RMB379.57b.
The SZSE Component Index now rose 165 points, or 1.1% to 15,277, with an overall
turnover of RMB242.12b.
Basic Information
=================
----------------------------------
Nominal 62.850 % Chg -5.20%
High 66.700 Low 62.850
Shares Tr 3.49m Turnover 223.14m
10-D SMA 66.045 %H.V 49.043
20-D SMA 71.028 VWAP 63.956
50-D SMA 72.797 RSI14 36.555
----------------------------------
Status: Active buy/sell ratio is 53:47, with net buying turnover of HK$12.72m, falling a
combined 7.37% over the past 2 consecutive trading days
Performance of stocks in the same sector or of relevance
========================================================
Stock (Code) Price (HK$) Change (%)
-----------------------------------------------
INNOVENT BIO (01801) 62.85 -5.20
GENSCRIPT BIO (01548) 40.85 +0.25
JXR (01951) 9.48 -0.32
JW THERAP-B (02126) 12.40 +3.51
BRII-B (02137) 37.25 -13.57
WUXI BIO (02269) 100.10 -0.40
BEIGENE (06160) 178.60 -2.62
CANSINOBIO-B (06185) 154.20 -0.52
KINTOR PHARMA-B (09939) 52.55 -5.06
ALPHAMAB-B (09966) 15.50 -6.51
-----------------------------------------------
(ed)